Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Clinical trial NCT03615326 · COMPLETED
Trial details
- NCT number
- NCT03615326
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-05
- Primary completion
- 2024-03-20
- Enrollment
- 738
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.